Nyrada (ASX:NYR) — Material Events
ASX:NYR · 15 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Nyrada Advances Xolatryp with Phase I Success and AU$8.25M RaiseMedium
Nyrada completes Phase I trial, plans Phase IIa for Xolatryp with AU$8.25M capital raise
21 Oct 2025
·Quarterly Activities Report & Appendix 4C
·85
Nyrada’s Xolatryp Phase I Trial Confirms Safety Ahead of Phase IIa LaunchMedium
Nyrada's Phase I Trial of Xolatryp™ Shows Positive Safety Results, Phase IIa Planned
6 Aug 2025
·Clinical Trial Update
·85
Nyrada Advances Xolatryp with Strong Phase I Safety and Promising Preclinical ResultsMedium
Nyrada’s Xolatryp Phase I trial progresses safely; preclinical studies show strong neuro and cardioprotection; Phase IIa trial planned; AU$2.93M cash at quarter end
31 July 2025
·Quarterly Activities Report & Appendix 4C
·85
Nyrada Secures $8.25M to Propel Xolatryp Phase IIa Heart Attack TrialMedium
Nyrada raises $8.25M to fund Phase IIa trial of Xolatryp in heart attack patients
4 Aug 2025
·Capital Raising
·85
Nyrada Clears Ethics Hurdle to Launch Phase IIa Heart Attack TrialMedium
Nyrada gets ethics approval to start Phase IIa trial of Xolatryp for heart attack treatment
8 Jan 2026
·Clinical Trial Announcement
·80
Nyrada Advances Xolatryp Phase IIa Trial with AU$6.74M Cash and Expanded Oncology ResearchMedium
Nyrada gains ethics approval for Phase IIa Xolatryp trial, reports AU$6.74M cash and AU$2.45M R&D rebate expected
15 Apr 2026
·Quarterly Activities Report & Appendix 4C
·80
Nyrada Advances Xolatryp Trial with Ethics Nod, Holds AU$7.12M CashMedium
Nyrada gets ethics approval for Phase IIa Xolatryp trial; strong cash position at AU$7.12M
23 Jan 2026
·Quarterly Activities Report & Appendix 4C
·80
Nyrada’s Xolatryp Advances with Strong Mitochondrial Protection DataMedium
Nyrada's Xolatryp Shows Mitochondrial Protection in Preclinical Studies, Phase IIa Trial on Track
16 Sept 2025
·Clinical Trial Update
·80
Nyrada’s Xolatryp Clears Safety Hurdle, Phase IIa Trial Set for Early 2026Medium
Nyrada's Xolatryp Phase I Trial Meets Safety Endpoints, Phase IIa Trial on Track for 2026
29 Sept 2025
·Clinical Trial Update
·80
Nyrada Launches Final Phase I Cohort for Xolatryp After Strong Safety SignalsMedium
Nyrada Commences Final Phase I Cohort for Xolatryp with No Safety Issues Reported
14 July 2025
·Clinical Trial Update
·80
Nyrada Advances Xolatryp to Phase IIa Trial Targeting Heart Attack DamageMedium
Nyrada to start Phase IIa trial of Xolatryp for heart attack treatment in early 2026
23 July 2025
·Clinical Trial Progress Announcement
·80
Nyrada Completes Phase I Dosing of Xolatryp with No Safety ConcernsMedium
Nyrada Completes Phase I Dosing of Xolatryp with No Safety Concerns
21 July 2025
·Clinical Trial Update
·80
Nyrada’s Xolatryp Advances as Losses Deepen to $3.19M in H1 2026Medium
Nyrada reports $3.19M half-year loss; Xolatryp advances to Phase IIa trial
18 Feb 2026
·Appendix 4D Half-year report
·70
Nyrada Inc. Faces Steep Losses Amid Revenue Drop in FY2025Medium
Nyrada Inc. reports 25% revenue decline and 248% higher net loss for FY2025
22 Aug 2025
·Appendix 4E Preliminary Final Report
·Unexpected
·70
Nyrada Clarifies Timing and Compliance in Disclosing Xolatryp Phase I Safety ResultsMedium
Nyrada confirms timely disclosure of positive Phase I trial safety results and compliance with ASX rules
14 Aug 2025
·ASX Compliance Response
·70
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Nyrada (ASX:NYR) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026
Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026
21 Feb 2026
Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026
25 Jan 2026